Table 1. Patient demographics and co-morbidities in the 6-month pre-index period and during selection period.
| Baseline characteristics | All patients | Naïve patients | ||||
|---|---|---|---|---|---|---|
| Total | Mild | Moderate to severe | Total | Mild | Moderate to severe | |
| N = 5162 | N = 1782 | N = 3380 | N = 2066 | N = 838 | N = 1228 | |
| Follow-up duration (days), Mean (SD) | 1064.7 (690.5) | 891.1 (654.5) | 1156.2 (691.5) | 992.9 (655.1) | 877.4 (635.8) | 1071.7 (656.5) |
| Age at index date, Mean (SD) | 49.7 (11.6) | 50.1 (12.1) | 49.5 (11.4) | 49.3 (11.7) | 49.6 (12.1) | 49.1 (11.4) |
| Age at index date by categories, n (%) | ||||||
| 18–34 | 597 (11.6) | 209 (11.7) | 388 (11.5) | 251 (12.1) | 106 (12.6) | 145 (11.8) |
| 35–44 | 1046 (20.3) | 353 (19.8) | 693 (20.5) | 420 (20.3) | 164 (19.6) | 256 (20.8) |
| 45–54 | 1568 (30.4) | 504 (28.3) | 1064 (31.5) | 644 (31.2) | 248 (29.6) | 396 (32.2) |
| 55–64 | 1508 (29.2) | 538 (30.2) | 970 (28.7) | 587 (28.4) | 244 (29.1) | 343 (27.9) |
| 65+ | 443 (8.6) | 178 (10.0) | 265 (7.8) | 164 (7.9) | 76 (9.1) | 88 (7.2) |
| Gender: Male, n (%) | 2229 (43.2) | 858 (48.1) | 1371 (40.6) | 890 (43.1) | 108 (38.7) | 782 (43.8) |
| Multiple medications (ATC code level 3) a | ||||||
| Mean (SD) | 6.3 (6.1) | 5.2 (5.3) | 6.9 (6.4) | 2.6 (3.8) | 2.8 (3.8) | 2.5 (3.8) |
| Median | 5.0 | 4.0 | 6.0 | 1.0 | 1.0 | 0.0 |
| Multiple medications (ATC code level 3) by categories of number of drugs, n (%) | ||||||
| 0 | 1047 (20.3) | 393 (22.1) | 654 (19.3) | 991 (48.0) | 358 (42.7) | 633 (51.5) |
| [1–3] | 978 (18.9) | 445 (25.0) | 533 (15.8) | 482 (23.3) | 221 (26.4) | 261 (21.3) |
| [4–5] | 751 (14.5) | 266 (14.9) | 485 (14.3) | 242 (11.7) | 101 (12.1) | 141 (11.5) |
| [6–8] | 624 (12.1) | 205 (11.5) | 419 (12.4) | 132 (6.4) | 59 (7.0) | 73 (5.9) |
| > 8 | 1762 (34.1) | 473 (26.5) | 1289 (38.1) | 219 (10.6) | 99 (11.8) | 120 (9.8) |
| Multiple medications (ATC code level 1) | ||||||
| Mean (SD) | 3.8 (3.0) | 3.3 (2.7) | 4.1 (3.1) | 1.8 (2.2) | 1.9 (2.2) | 1.7 (2.2) |
| Median | 4.0 | 3.0 | 4.0 | 1 | 1.0 | 1.0 |
| Multiple medications (ATC code level 1) by categories of number of drugs, n (%) | ||||||
| 0 | 966 (18.7) | 363 (20.4) | 603 (17.8) | 946 (45.8) | 344 (41.1) | 602 (49.0) |
| [1–3] | 1580 (30.6) | 671 (37.7) | 909 (26.9) | 700 (33.9) | 319 (38.1) | 381 (31.0) |
| [4–5] | 1132 (21.9) | 363 (20.4) | 769 (22.8) | 258 (12.5) | 99 (11.8) | 159 (12.9) |
| [6–8] | 817 (15.8) | 239 (13.4) | 578 (17.1) | 116 (5.6) | 54 (6.4) | 62 (5.0) |
| > 8 | 667 (12.9) | 146 (8.2) | 521 (15.4) | 46 (2.2) | 22 (2.6) | 24 (2.0) |
| CCI | ||||||
| Mean (SD) | 0.4 (0.9) | 0.3 (0.8) | 0.4 (0.9) | 0.2 (0.7) | 0.3 (0.7) | 0.2 (0.7) |
| Median | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Comorbidity at baseline, n (%) | ||||||
| Rheumatoid arthritis | 104 (2.0) | 10 (0.6) | 94 (2.8) | 14 (0.7) | 4 (0.5) | 10 (0.8) |
| Inflammatory bowel disease | 76 (1.5) | 16 (0.9) | 60 (1.8) | 15 (0.7) | 6 (0.7) | 9 (0.7) |
| Ankylosing spondylitis | 3 (0.1) | 0 (0.0) | 3 (0.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Juvenile arthritis | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Psoriasis | 164 (3.2) | 36 (2.0) | 128 (3.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Comorbidity at selection period n (%) | ||||||
| Rheumatoid arthritis during selection period | 248 (4.8) | 22 (1.2) | 226 (6.7) | 64 (3.1) | 8 (1.0) | 56 (4.6) |
| Inflammatory bowel disease during selection period | 195 (3.8) | 33 (1.9) | 162 (4.8) | 50 (2.4) | 13 (1.6) | 37 (3.0) |
| Ankylosing spondylitis during selection period | 7 (0.1) | 1 (0.1) | 6 (0.2) | 1 (0.0) | 0 (0.0) | 1 (0.1) |
| Juvenile arthritis during selection period | 1 (0.0) | 0 (0.0) | 1 (0.0) | 1 (0.0) | 0 (0.0) | 1 (0.1) |
| Psoriasis during selection period | 602 (11.7) | 155 (8.7) | 447 (13.2) | 183 (8.9) | 74 (8.8) | 109 (8.9) |
| Treatment experience | ||||||
| naïve | 2066 (40.0) | 838 (47.0) | 1228 (36.3) | 2066 (100.0) | 838 (100.0) | 1228 (100.0) |
| Experienced | 3042 (58.9) | 894 (50.2) | 2148 (63.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| NA | 54 (1.0) | 50 (2.8) | 4 (0.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Medical intervention experience | ||||||
| GMA: Granulocyte Monocyte Apheresis | 1 (0.0) | 1 (0.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Tonsillectomy | 32 (0.6) | 7 (0.4) | 25 (0.7) | 12 (0.6%) | 5 (0.6) | 7 (0.6) |
a: Multiple medication were evaluated by the number of drugs prescribed (by 3-digit ATC classes).
CCI: Charlson Comorbidity Index.
NA: Not applicable.